- Home
- ESTC vs MDGL Comparison
ESTC vs MDGL Comparison
Compare ESTC & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESTC
- MDGL
- Stock Information
- Founded
- ESTC 2012
- MDGL 2011
- Country
- ESTC Netherlands
- MDGL United States
- Employees
- ESTC N/A
- MDGL N/A
- Industry
- ESTC Computer Software: Prepackaged Software
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- ESTC Technology
- MDGL Health Care
- Exchange
- ESTC Nasdaq
- MDGL Nasdaq
- Market Cap
- ESTC N/A
- MDGL 6.1B
- IPO Year
- ESTC 2018
- MDGL N/A
- Fundamental
- Price
- ESTC $84.04
- MDGL $311.14
- Analyst Decision
- ESTC Buy
- MDGL Strong Buy
- Analyst Count
- ESTC 26
- MDGL 9
- Target Price
- ESTC $115.74
- MDGL $420.63
- AVG Volume (30 Days)
- ESTC 1.6M
- MDGL 283.6K
- Earning Date
- ESTC 08-28-2025
- MDGL 08-06-2025
- Dividend Yield
- ESTC N/A
- MDGL N/A
- EPS Growth
- ESTC N/A
- MDGL N/A
- EPS
- ESTC N/A
- MDGL N/A
- Revenue
- ESTC $1,483,296,000.00
- MDGL $317,383,000.00
- Revenue This Year
- ESTC $14.61
- MDGL $286.17
- Revenue Next Year
- ESTC $12.41
- MDGL $64.17
- P/E Ratio
- ESTC N/A
- MDGL N/A
- Revenue Growth
- ESTC 17.04
- MDGL N/A
- 52 Week Low
- ESTC $69.00
- MDGL $200.63
- 52 Week High
- ESTC $123.96
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- ESTC 47.71
- MDGL 58.78
- Support Level
- ESTC $83.00
- MDGL $284.02
- Resistance Level
- ESTC $86.54
- MDGL $327.59
- Average True Range (ATR)
- ESTC 2.53
- MDGL 12.53
- MACD
- ESTC 0.19
- MDGL 2.52
- Stochastic Oscillator
- ESTC 42.65
- MDGL 67.07
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.